Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

被引：18
|
作者：
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Yanli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Zeng, Shan
Men, Lichuang
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Lu, Ming
Wang, Hengbang
Ji, Jiao
Yue, Changai
Yang, Dajun
Zhai, Yifan
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142142
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 46 条
  • [1] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Hou, Yue
    Hu, Yu
    Li, Weiming
    Liu, Xiaoli
    Xu, Na
    Song, Yongping
    Zhang, Gongli
    Meng, Li
    Hong, Zhenya
    Liu, Bingcheng
    Li, Yan
    Chen, Suning
    Xue, Mengxing
    Zhu, Huanling
    Li, He
    Du, Xin
    Lou, Jin
    Zhang, Xiaohan
    Liang, Yang
    Dai, Yujun
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    BLOOD, 2021, 138
  • [2] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 15
  • [3] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 16
  • [4] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Qin, Yazhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huan, Xiaojun
    BLOOD, 2021, 138
  • [5] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)
    Jiang, Qian
    Li, Zongru
    Qin, Yazhen
    Li, Weiming
    Xu, Na
    Liu, Bingcheng
    Zhang, Yanli
    Meng, Li
    Zhu, Huanling
    Du, Xin
    Chen, Suning
    Liang, Yang
    Hu, Yu
    Liu, Xiaoli
    Song, Yongping
    Men, Lichuang
    Chen, Zi
    Niu, Qian
    Wang, Hengbang
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [6] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022)
    Jiang, Qian
    Li, Zongru
    Qin, Yazhen
    Li, Weiming
    Xu, Na
    Liu, Bingcheng
    Zhang, Yanli
    Meng, Li
    Zhu, Huanling
    Du, Xin
    Chen, Suning
    Liang, Yang
    Hu, Yu
    Liu, Xiaoli
    Song, Yongping
    Men, Lichuang
    Chen, Zi
    Niu, Qian
    Wang, Hengbang
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [7] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
    Jiang, Qian
    Li, Zongru
    Hou, Yue
    Hu, Yu
    Li, Weiming
    Liu, Xiaoli
    Xu, Na
    Zhang, Yanli
    Song, Yongping
    Meng, Li
    Hong, Zhenya
    Liu, Bingcheng
    Li, Yan
    Chen, Suning
    Xue, Mengxing
    Zhu, Huanling
    Li, He
    Du, Xin
    Lou, Jin
    Zhang, Xiaohan
    Liang, Yang
    Dai, Yu-Jun
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiao-Jun
    BLOOD, 2022, 140
  • [8] An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
    Jiang, Qian
    Huang, Xiaojun
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Huang, Bo
    Shi, Dayu
    Zhao, Ting
    Hou, Yue
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2019, 134
  • [9] A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
    Jiang, Qian
    Li, Zongru
    Qin, Ya-Zhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiao-Jun
    BLOOD, 2022, 140
  • [10] Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor(TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy
    Yu, Lu
    Men, Lichuang
    Li, Zongru
    Huang, Xiaojun
    Jiang, Qian
    BLOOD, 2023, 142
12345